This is an excerpt from todays Press ReleaseSHAWNEE MISSION, Kan., April 23 /PRNewswire-FirstCall/ -- Bayer said it is pleased at the results of two independent scientific studies that show banning the use of Baytril® 3.23% enrofloxacin for the treatment of air sacculitis, a pneumonia-like infection in poultry, could potentially compromise food safety and have a significant negative impact on human health."These studies strongly support the continued therapeutic use of Baytril for poultry and clearly identify the human health benefit, a factor that has not yet been fully considered by FDA," said John B. Payne, president and general manager, Bayer HealthCare LLC, Animal Health Division.http://biz.yahoo.com/prnews/030423/phw026_1.html
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Rat